易慕峰生物递表港交所 为全球领先的创新型细胞治疗公司

Company Overview - Yimufeng Biotech is a leading global innovative cell therapy company, with its core product IMC002 being a potential best-in-class anti-CLDN18.2 CAR-T cell therapy candidate, currently in pivotal Phase III clinical trials for solid tumors [2] - The company also has a first-in-class anti-EpCAM CAR-T cell therapy candidate (IMC001) in Phase I/IIa clinical trials, targeting various epithelial-derived tumors, and a proprietary manufacturing process for cost-effective CAR-T production [3] - Yimufeng Biotech aims to leverage the large patient population for solid tumors in China and globally, creating significant market potential [2] Financial Information - For the fiscal year 2024, the company reported other income and revenue of approximately 3.36 million RMB, 2.137 million RMB for the nine months ended September 30, 2024, and 2.877 million RMB for the nine months ended September 30, 2025 [4] - Research and development expenses for the fiscal year 2024 were recorded at 54.44 million RMB, 38.574 million RMB for the nine months ended September 30, 2024, and 48.694 million RMB for the nine months ended September 30, 2025 [5] Industry Overview - CAR-T therapy is expanding significantly from hematologic malignancies to solid tumors and autoimmune diseases, presenting substantial growth opportunities [8] - The treatment shows promising efficacy against blood cancers, and researchers are developing innovative strategies to address challenges in solid tumor treatment [8] - The CAR-T field is evolving through traditional technology improvements and the development of new platforms, with next-generation CAR designs enhancing targeting precision and safety [8]